[Chromogenic substrate as antidote against the thrombin inhibitor Melagatran?].
It could be shown in vitro that a chromogenic substrate (Chromozym TH, Roche Mannheim) acts at least partially as antidote against the new thrombin inhibitor Melagatran (AstraZeneca, Mölndal, Sweden). It is discussed that this antidote effect of a chromogenic substrate might be due to a substrate competition of fibrinogen, thrombin inhibitor, and chromogenic substrate for thrombin. Further animal experiments will clarify whether this in vitro observation is of practical relevance in vivo, too.
I. Medizinische Universitätsklinik Kiel, Schittenhelmstrasse 12, 24105 Kiel.
I
I
Bodendiek
S
S
Lentz
M
M
Seeger
H D
HD
Bruhn
D000931:Antidotes; D000991:Antithrombins / Q000633:toxicity*; D001384:Azetidines; D001596:Benzylamines; D002863:Chromogenic Compounds / Q000627:therapeutic use*; D005998:Glycine / Q000031:analogs & derivatives* / Q000633:toxicity*; D006801:Humans; D009842:Oligopeptides / Q000627:therapeutic use*
D000931:Antidotes; D000991:Antithrombins; D001384:Azetidines; D001596:Benzylamines; D002863:Chromogenic Compounds; D009842:Oligopeptides; C109573:melagatran; C014413:chromozym TH; D005998:Glycine